|
Esquemas con sofosbuvir y simeprevir en hepatitis C [Sofosbuvir and simeprevir-based schemes for the management of hepatitis C] |
Calderón C, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A, López A, Rey-Ares L |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Calderón C, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A, López A, Rey-Ares L. Esquemas con sofosbuvir y simeprevir en hepatitis C. [Sofosbuvir and simeprevir-based schemes for the management of hepatitis C] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 430. 2015 Authors' objectives To assess the available evidence on the efficacy, safety and aspects related to coverage polices on the use of sofosbuvir and simeprevir schemes for the management of patients with chronic hepatitis C.
Chronic hepatitis C virus (HCV) infection is one of the main causes of cirrhosis and hepatocelullar carcinoma worldwide. HCV is an ARN virus with six genotypes (1 to 6); genotype 1 being the most common in Argentina (70%). The main objective of this therapy is to cure infection. This is called sustained virologic response (SVR) and it is reflected by measuring undetectable HCV ARN in blood once therapy is completed. Treatment with pegylated interferon (PegIFN) + ribavirin (RBV) has been the main management scheme for many years. New, more efficacious and safer schemes such as sofosbuvir (SOF), simeprevir (SIM), daclatasvir and ledipasvir among others have currently appeared; they can even be administered to subjects with decompensated cirrhosis.
The use of SOF and SIM schemes has been proposed for the treatment of chronic hepatitis C because higher SVRs could be obtained, with lower adverse effect rates and shorter treatment length compared with the standard treatment.
SOF is a virus RNA analogue polymerase inhibitor, whereas SIM is an NS3-4a serine protease HCV inhibitor. These two drugs have been evaluated in combination with other drugs for hepatitis C management, that is to say, they are not administered as monotherapy. Authors' conclusions There is plenty of evidence found and its good quality. Schemes with sofosbuvir and simeprevir combined with other drugs to manage hepatitis C have demonstrated to be better when compared with the standard treatment or triple therapy with telaprevir or boceprevir in different patient groups. Although they are considered in the different clinical practice guidelines and health technology assessment documents, their high cost may limit their treatment availability in the different countries. Indexing Status Subject indexing assigned by CRD MeSH Hepacivirus; Hepatitis C; Humans; Sulfonamides Language Published Spanish Country of organisation Argentina English summary An English language summary is available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32015001160 Date abstract record published 17/11/2015 |
|
|
|